Your browser doesn't support javascript.
loading
Long-term outcome of patients with polymyositis/ dermatomyositis and anti-PM-Scl antibody.
Marie, I; Lahaxe, L; Benveniste, O; Delavigne, K; Adoue, D; Mouthon, L; Hachulla, E; Constans, J; Tiev, K; Diot, E; Levesque, H; Boyer, O; Jouen, F.
Afiliação
  • Marie I; Department of Internal Medicine, CHU Rouen, 76031 Rouen Cedex, France. isabelle.marie@chu-rouen.fr
Br J Dermatol ; 162(2): 337-44, 2010 Feb 01.
Article em En | MEDLINE | ID: mdl-19845665
ABSTRACT

BACKGROUND:

To date, no series has analysed long-term outcome in patients with polymyositis/dermatomyositis (PM/DM) with anti-PM-Scl antibody.

OBJECTIVES:

The aims of the present study were (i) to assess clinical features and long-term outcome, including organ complications, functional course and mortality rate, in patients with isolated PM/DM with anti-PM-Scl antibody; and (ii) to evaluate prevalence, characteristics and long-term outcome of interstitial lung disease (ILD) in patients with isolated PM/DM with anti-PM-Scl antibody.

METHODS:

The medical records of 20 consecutive patients with isolated PM/DM with anti-PM-Scl antibody were reviewed.

RESULTS:

Two patients (10%) achieved remission of PM/DM, whereas 14 (70%) improved and four (20%) had a worsened clinical status. Short-term recurrences (during tapering of therapy) occurred in nine patients and long-term recurrences (after discontinuation of therapy) in three patients. Moreover, patients with PM/DM with anti-PM-Scl antibody exhibited severe complications, as follows oesophageal involvement (n = 4) requiring enteral feeding in three cases, ventilatory insufficiency (n = 3) requiring mechanical ventilation in two cases; three other patients had cancer. Interestingly, patients with PM/DM with anti-PM-Scl antibody often presented symptoms that are usually found in antisynthetase syndrome, i.e. hyperkeratotic rhagadiform hand symptoms (n = 2; 10%), Raynaud's phenomenon (n = 8; 40%), arthralgia/arthritis (n = 7; 35%) and ILD (n = 12; 60%). In our cohort, the associated ILD often required combined therapy of steroids and immunosuppressive agents.

CONCLUSIONS:

Our series suggests that the presence of anti-PM-Scl antibody is not a good prognostic factor in patients with PM/DM, as there appears to be an association with lung and oesophageal involvement; in addition, anti-PM-Scl antibody may coexist with malignancy in patients with PM/DM. Furthermore, anti-PM-Scl antibody-positive patients with PM/DM often exhibit 'mechanic's hands', Raynaud's phenomenon and joint involvement. Our latter findings raise the possibility that the immunogenetic background influences the autoantibody status of these patients; HLA-DR3 has, in fact, been found in association with antisynthetase syndrome antibodies and with anti-PM-Scl antibodies.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Nucleares / Anticorpos Anti-Idiotípicos / Dermatomiosite / Exorribonucleases / Imunossupressores Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Dermatol Ano de publicação: 2010 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Nucleares / Anticorpos Anti-Idiotípicos / Dermatomiosite / Exorribonucleases / Imunossupressores Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Dermatol Ano de publicação: 2010 Tipo de documento: Article País de afiliação: França